PROCEEDINGS OF SPIE

SPIDigitalLibrary.org/conference-proceedings-of-spie

Front Matter: Volume 10306

, "Front Matter: Volume 10306," Proc. SPIE 10306, Future Directions and Applications in Photodynamic Therapy, 1030601 (21 January 1990); doi: 10.1117/12.2283663

SPIE.

Event: SPIE Institutes for Advanced Optical Technologies 6, 1990, San Diego, California, United States

Preface

The concept of the Institutes for Advanced Optical Technologies developed out of SPIE's desire to foster increased interaction and collaboration among researchers working in emerging optical technologies. The Institutes provide a forum for experts in these areas to analyze and document the state of the art and to point toward future trends and applications. Institute topics are selected for their timeliness as well as for their significance to future progress in the application of optics. Institute organizers invite selected experts to participate as paper contributors and discussion participants. It is intended that the interaction generated by the small-group structure in a retreat-like setting will foster productive discussions that are beyond the scope and possibility of a regular conference format.

Each Institute has two primary objectives: first, that the interactions and dialogue stimulate technical advancement, and second, that the publication of the Institute volume results in an authoritative collection of significant papers covering key topics in the field. While each editor and committee has unique criteria for determining the acceptability of contributions, it is intended that the Institute process itself will establish the worth and appropriateness of the individual contributions. Each contributor is asked to prepare a draft manuscript and circulate it to the other participants in advance of the Institute. The editor/chair organizes an agenda for discussing critical technical issues. The interactions and congenial discussions by the Institute members are the basis for the ensuing Institute volume. The final action of the Institute is to decide the scope of the volume and what material is to be included and what other material is to be added and by whom.

The Institute on photodynamic therapy, held January 19–21, 1990, in San Diego, addressed the future outlook and critical technical issues related to research and clinical development in PDT. The Institute forum gave the participants an opportunity to present and discuss in depth different approaches and expectations for the future development of PDT. It was especially fruitful to have the blend of technical interests represented by the participants—biochemists, clinicians, and engineers, all with a common interest in PDT.

This volume contains papers by the Institute participants and their research colleagues. Topics range from a review of the status of PDT clinical trials, studies into new photosensitizers, requirements in laser and fiber optic technologies for light delivery, to studies of the biological mechanisms behind PDT action.

Roy F. Potter

General Editor, SPIE Institutes for Advanced Optical Technologies

Other publications in the SPIE Institutes for Advanced Optical Technologies series:

Transformations in Optical Signal Processing, William T. Rhodes, James R. Fienup, Bahaa E. A. Saleh, Editors, 1984, SPIE Volume 373 (Out of print)

Optical and Hybrid Computing, Harold H. Szu, Editor, 1987, SPIE Volume 634

Photonics: High Bandwidth Analog Applications, James Chang, Editor, 1987, SPIE Volume 648

Large-Area Chromogenics: Materials and Devices for Transmittance Control, Carl M. Lampert, Claes G. Granqvist, Editors, 1990, Volume IS 4

Dosimetry of Laser Radiation in Medicine and Biology, Gerhard J. Müller, David H. Sliney, Editors, 1989, Volume IS 5

Future Directions and Applications in Photodynamic Therapy

Contents

iii	Preface
vii	Institute Participants
ix	Introduction
1	Future of photodynamic therapy: is there one? T. J. Dougherty, Roswell Park Cancer Institute
5	Photodynamic therapy of human cancer: clinical status, potential, and needs S. L. Marcus, American Cyanamid Co.
57	Photodynamic therapy: priorities for 1990 D. Kessel, Wayne State Univ. School of Medicine
64	Oxygen monitoring during photodynamic therapy B. J. Tromberg, Beckman Laser Institute and Medical Clinic, Univ. of California/Irvine; S. Kimel, Technion-Israel Institute of Technology (Israel); A. Orenstein, Sheba Medical Ctr. (Israel); J. S. Nelson, M. W. Berns, Beckman Laser Institute and Medical Clinic, Univ. of California/Irvine
71	Syntheses of some new porphyrin photosensitizers for photodynamic therapy F.-Y. Shiau, P. A. Liddell, M. G. H. Vicente, N. V. Ramana, K. Ramachandran, S.-J. H. Lee, Univ. of California/Davis; R. K. Pandey, Oncologic Foundation of Buffalo; T. J. Dougherty, Roswell Park Cancer Institute; K. M. Smith, Univ. of California/Davis
87	Second-generation sensitizers: where are we and where should we be going? A. R. Morgan, D. Skalkos, Univ. of Toledo
107	Prospects of phthalocyanines as photosensitizers for the photodynamic therapy of cancer J. E. van Lier, Univ. of Sherbrooke (Canada)
115	Chemical mechanisms of photodynamic action C. S. Foote, Univ. of California/Los Angeles
127	Photosensitization with deep red light M. A. J. Rodgers, Bowling Green State Univ.
139	Basic mechanisms and subcellular targets related to PDT C. J. Gomer, A. Ferrario, M. Luna, N. Rucker, S. Wong, Childrens Hospital of Los Angeles
153	Significance of vascular photosensitization in photodynamic therapy B. W. Henderson, Roswell Park Cancer Institute

167	Approaches to improved delivery of photosensitizers B. Allison, A. M. Richter, F. Jiang, Univ. of British Columbia (Canada); S. Jiang, D. Liu, Quadra Logic Technologies, Inc. (Canada); J. G. Levy, Univ. of British Columbia (Canada)
177	New approaches to photochemotherapy: cationic sensitizers and multiagent combination therapies A. R. Oseroff, Roswell Park Cancer Institute
195	Psoralen photobiology and photochemotherapy: perspectives and prospects F. P. Gasparro, Yale Univ.
209	Photodynamic therapy and bone marrow transplantation F. Sieber, Medical College of Wisconsin
219	Optical fiber-based diffuse reflectance spectrometer for noninvasive investigation of photodynamic sensitizers in vivo B. C. Wilson, Hamilton Regional Cancer Ctr., McMaster Univ., and Ontario Laser and Lightwave Research Center (Canada); T. J. Farrell, M. S. Patterson, Hamilton Regional Cancer Ctr. and McMaster Univ. (Canada)
233	On the physical rationale of photodynamic therapy L. O. Svaasand, Univ. of Trondheim (Norway); C. J. Gomer, E. Morinelli, Childrens Hospital of Los Angeles
249	Photodynamic therapy of early cancer in the upper aerodigestive tract and bronchi: instrumentation and clinical results G. Wagnières, Swiss Federal Institute of Technology (Switzerland); P. Monnier, M. Savary, CHUV Hospital (Switzerland); P. F. Cornaz, A. Châtelain, H. van den Bergh, Swiss Federal Institute of Technology (Switzerland)
272	Optical-CCD system for imaging light and drug distributions in tumors for phototherapy R. C. Straight, Univ. of Utah; P. M. N. Y. H. Go, Univ. Hospital of Maastricht (Netherlands); R. E. Benner, J. A. Dixon, R. W. McClane, Univ. of Utah
282	Author Index

Institute Participants

Michael W. Berns

Beckman Laser Institute and Medical Clinic
University of California-Irvine
1002 Health Sciences Road East
Irvine, CA 92715

Daniel R. Doiron

Laserguide, Inc.
51 Santa Felicia Drive
Santa Barbara, CA 93117

Thomas J. Dougherty

Roswell Park Cancer Institute
Department of Radiation Medicine
666 Elm Street
Buffalo, NY 14263

Christopher S. Foote

University of California-Los Angeles
Department of Chemistry and Biochemistry
Los Angeles, CA 90024

Francis P. Gasparro

Yale University
Department of Dermatology
Hunter Radiation Laboratory
333 Cedar Street
New Haven, CT 06510

Charles J. Gomer

Childrens Hospital of Los Angeles
USC School of Medicine
4650 Sunset Boulevard
Los Angeles, CA 90027

Barbara W. Henderson

Roswell Park Cancer Institute
Division of Radiation Biology
Elm and Carlton Streets
Buffalo, NY 14263

David Kessel

Wayne State University School of Medicine
Departments of Pharmacology and Medicine
540 East Canfield
Detroit, MI 48201

Julia G. Levy

Quadra Logic Technologies, Inc.
520 W. 6th Avenue
Vancouver, British Columbia
V5Z 4H5 Canada

Stuart L. Marcus

American Cyanamid Company
Medical Research Division
Lederle Laboratories
North Middletown Road
Pearl River, NY 10965

Alan R. Morgan

University of Toledo
Department of Chemistry
2801 West Bancroft Street
Toledo, OH 43606-3390

Allan R. Oseroff

Roswell Park Cancer Institute
Department of Dermatology
Elm and Carlton Streets
Buffalo, NY 14263

Michael A. J. Rodgers

Bowling Green State University
Center for Photochemical Sciences
Bowling Green, OH 43403

Fritz Sieber

Medical College of Wisconsin
Department of Pediatrics
8701 Watertown Plank Road
Milwaukee, WI 53226

Kevin M. Smith

University of California-Davis
Department of Chemistry
Davis, CA 95616

Richard C. Straight

University of Utah
Laser Institute VAMC
500 Foothill Drive
Salt Lake City, UT 84132

Lars O. Svaasand

University of Trondheim
Norwegian Institute of Technology
Trondheim, N-7034
Norway

Bruce J. Tromberg

Beckman Laser Institute and Medical Clinic
University of California-Irvine
1002 Health Sciences Road East
Irvine, CA 92715-3054

Hubert van den Bergh

Swiss Federal Institute of Technology
Laboratory of Chemical Technology
Lausanne, CH-1015
Switzerland

Johan E. van Lier

University of Sherbrooke
Faculty of Medicine
MRC Group in Radiological Sciences
Sherbrooke, Quebec J1H 5N4
Canada

Brian C. Wilson

Hamilton Regional Cancer Center
Department of Medical Physics
711 Concession Street
Hamilton, Ontario L8V 1c3
Canada

Introduction

Photodynamic therapy (PDT) is the treatment of malignant lesions with visible light following the systemic administration of tumor-localizing photosensitizers. The therapy takes advantage of the unique properties of laser-generated light sources and fiber optic delivery systems. Clinical applications of PDT in the treatment of solid tumors have a 15-year history, and a number of promising anecdotal studies have been reported. However, the first controlled Phase III clinical trials are only now being performed and the true potential of PDT has yet to be realized. Continued efforts to define photochemical and photophysical properties of photosensitizers used in PDT, as well as additional studies focused on identifying targets and mechanisms of action associated with PDT, should provide a solid foundation for understanding and exploiting the applications of this therapy. Likewise, the synthesis of new photosensitizers and the continued development of laser and dosimetry systems should play a significant role in the future refinement of PDT.

The goal of the SPIE Institute on Photodynamic Therapy was to provide an informal forum in which experts in various preclinical and clinical disciplines of PDT could debate current applications and future directions. As a result of this endeavor, the participants have written chapters for this book that provide new information on current research in PDT, as well as suggestions for future studies.

I'd like to thank Tom Dougherty, Barbara Henderson, and Lars Svaasand for their contributions as discussion leaders during the Institute, as well as all the participants for their contributions. I also thank Roy Potter for his support in bringing this Institute together. Finally, the financial assistance and organizational skills of SPIE are gratefully acknowledged. All of the participants express their sincere appreciation to SPIE and its staff for an extremely productive and enjoyable conference.

Charles J. Gomer

Childrens Hospital of Los Angeles

University of Southern California School of Medicine